Related Links
Statistics
| Number of Journals | 8 |
| Number of Issues | 52 |
| Number of Articles | 381 |
| Article View | 113,378 |
| PDF Download | 79,777 |
AL amyloidosis with cardiac involvement: a case report with literature review | ||
| Cardiovascular Biomedicine | ||
| Volume 5, Issue 1, September 2025, Pages 3-9 PDF (584.07 K) | ||
| Document Type: case report | ||
| DOI: 10.18502/cbj.v5i1.19445 | ||
| Authors | ||
| Sanjay Arya1; Venus Shahabi Rabori* 1; Sara Azeem2 | ||
| 1Department of Cardiology, Royal Albert Edward Infirmary of Wigan, Wwl NHS Trust, UK | ||
| 2Medicine, Royal Albert Edward Infirmary of Wigan, Wwl NHS Trust, UK | ||
| Abstract | ||
| Objectives: To present a case of rapidly progressing cardiac immunoglobulin light chain (AL) amyloidosis, highlighting diagnostic challenges, management complexities, and the importance of early intervention. AL amyloidosis is a rare and severe disorder that causes organ damage, especially in the heart, leading to restrictive cardiomyopathy, heart failure, and arrhythmias. This case report highlights diagnostic difficulties and management issues, showcasing advanced imaging techniques and a multidisciplinary approach. Methods: A 68-year-old man presented to Wigan Infirmary, Wrightington, Wigan, and Leigh (WWL) NHS Trust in July 2024 with dyspnea, nocturnal cough, and decreased exercise tolerance due to rapidly progressing cardiac AL amyloidosis. The diagnostic workup included chest X-ray, echocardiography, cardiac MRI, and a Technetium-99m-labeled 3, 3-diphosphono-1, 2-propanodicarboxylic acid (Tc-DPD) scan. Fat aspirate biopsy confirmed the diagnosis by showing Congo red positivity with characteristic apple-green birefringence under polarized light. Laboratory tests supported the diagnosis, revealing lambda free light chain levels over 2000 mg/L, elevated B-type natriuretic peptide (BNP) at 4174 pg/mL, and impaired kidney function. This case emphasizes the importance of early detection and treatment of cardiac amyloidosis, as well as the difficulties of managing this condition alongside concurrent infections. Results: Despite early diagnosis and vigorous treatment, the patient's condition rapidly declined, leading to several hospitalizations for decompensated heart failure and infections. Treatment focused on reducing amyloid production and managing cardiac issues. For infection-related admissions, the treatment regimen included intravenous furosemide, dexamethasone, and piperacillin-tazobactam (Tazocin). However, over these admissions, the patient’s condition worsened due to recurring infections and the progressive decline in renal and hepatic function. Sadly, the patient died in early January 2025 during the final hospitalization due to severe refractory heart failure. Conclusions: The case highlights the vital importance of early detection and a multidisciplinary approach to managing cardiac AL amyloidosis. It stresses the need for collaboration among various specialties, including cardiology, hematology, and infectious disease, to effectively handle the complexities of concurrent cardiac failure, arrhythmias, and infections. This coordinated care approach is essential for optimizing treatment planning and orders. | ||
| Keywords | ||
| Restrictive cardiomyopathy; AL amyloidosis; cardiac amyloidosis; heart failure; lambda free light chains; Tc-DPD scan; fat aspirate biopsy; multidisciplinary approach; infection; renal dysfunction | ||
| References | ||
|
1.Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387 (10038): 2641-2654.
2.Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2(10):1046-1053.
3.Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18): 3751-7.
4.Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021; 42(16):1554-1568.
5.Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 2021; 11(5):90.
6.Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30(9):989-95.
7.Bhogal S, Ladia V, Sitwala P, et al. Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions. Curr Probl Cardiol. 2018; 43(1)10-34.
8.Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019; 12(5):823-833.
9.Martinez-Naharro A, Baksi AJ, Hawkins PN, et al. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020; 17(7):413-426.
10.Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015; 132(16):1570-9.
11.Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovasc Imaging. 2020; 13(6):1299-1310.
12.Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46(6):1076-84.
13.Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018; 45(11): 1945-1955.
14.Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/ SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence-based and standardized methods of imaging. J Nucl Cardiol. 2019; 26(6):2065-2123.
15.Maceira AM, Prasad SK, Hawkins PN, et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008; 10(1):54.
16.Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133(24):2404-12.
17.Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013; 121(17):3420-7.
18.Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013; 98 (10):1492-5.
19. Sidana S, Tandon N, Brady PA, et al. Prognostic significance of Holter monitor findings in patients with light chain amyloidosis. Mayo Clin Proc. 2019;94(3):455–464. | ||
|
Statistics Article View: 57 PDF Download: 13 |
||